IFACX
Price
$24.37
Change
-$0.13 (-0.53%)
Updated
Dec 17 closing price
RIDAX
Price
$24.61
Change
-$0.13 (-0.53%)
Updated
Dec 17 closing price
Ad is loading...

IFACX vs RIDAX

Header iconIFACX vs RIDAX Comparison
Open Charts IFACX vs RIDAXBanner chart's image
American Funds Income Fund of Amer C
Price$24.37
Change-$0.13 (-0.53%)
VolumeN/A
CapitalizationN/A
American Funds Income Fund of Amer R1
Price$24.61
Change-$0.13 (-0.53%)
VolumeN/A
CapitalizationN/A
IFACX vs RIDAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
IFACX vs. RIDAX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IFACX is a Buy and RIDAX is a Buy.

FUNDAMENTALS
Fundamentals
IFACX (123B) and RIDAX (123B) have equal amount of cash in the bank . IFACX (2.88) and RIDAX (2.82) have matching dividends . IFACX was incepted earlier than RIDAX: IFACX (24 years) vs RIDAX (23 years). IFACX (40.00) and RIDAX (40.00) have comparable annual turnover. IFACX (250) and RIDAX (250) have matching initial minimum investment requirements. RIDAX (10.05) and IFACX (10.04) have marching annual gain over last year. RIDAX (17.26) and IFACX (17.22) have equivalent 5 years return.
IFACXRIDAXIFACX / RIDAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years23 years-
Gain YTD8.7008.721100%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets123B123B100%
Annual Yield % from dividends2.882.82102%
Returns for 1 year10.0410.05100%
Returns for 3 years4.464.5199%
Returns for 5 years17.2217.26100%
Returns for 10 years27.9028.1199%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OPK1.610.01
+0.62%
OPKO Health
PFG77.54-1.13
-1.44%
Principal Financial Group
HI30.81-0.69
-2.19%
Hillenbrand
VRA3.88-0.10
-2.51%
Vera Bradley
BTAI0.39-0.02
-4.01%
BioXcel Therapeutics